Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Innate Pharma S.A.NASDAQ: IPHA

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue turns positive

Q4 FY2025 cost of revenue was €0, compared with -€29.08M a year earlier.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 411.9 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€0— QoQ
Last fiscal yearDec 2025
€0-100.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
0 EUR
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -100.0% is the lowest of 6, against a peer median of -75.2%.
  • Cost of revenue amounts to 0.0% of revenue for IPHA, versus a peer median of 8.6%.
IPHA Competitors
Cost of Revenue for IPHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDFCardiff Oncology, Inc.LTM Mar 2026$11.58M USD+18.8%—2205.7%
CGENCompugen Ltd.LTM Mar 2026$8.68M USD+5.4%+111.7%11.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF-92.3%-62.9%—
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$161K USD——5.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$149K USD-99.1%——
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
Peer median (excluding IPHA) —-75.2%+2.2%8.6%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.11M57.67M51.9M12.62M2.79M
Cost of Revenue47M51.66M56.02M51.98M0
Gross Profit(22.3M)6.01M5.62M12.62M2.79M
Gross Margin-184.1%10.4%10.8%100.0%100.0%
Research & Development47M51.66M56.02M51.98M43.62M
Selling, General & Admin25.52M14.47M11.75M11.93M11M
Operating Expenses25.52M63.44M18.29M64.2M56.21M
Depreciation & Amortization4.6M45.41M5.09M1.99M5.09M
EBITDA(43.23M)(12.28M)(1.84M)(46.91M)(43.65M)
EBITDA Margin-356.9%-21.3%-3.5%-371.7%-1566.1%
Operating Income(47.83M)(57.43M)(12.67M)(51.58M)(53.43M)
Operating Margin-394.9%-99.6%-24.4%-408.6%-1916.9%
Interest Income327K546K3.18M2.44M1.32M
Interest Expense312K288K640K566K440K
Other Income / Expenses2.35M(547K)5.1M2.1M4.25M
Income Before Tax(45.48M)(57.97M)(7.57M)(49.47M)(49.18M)
Pre-Tax Margin-375.5%-100.5%-14.6%-392.0%-1764.5%
Income Tax Expense00000
Net Income(52.81M)(58.1M)(7.57M)(49.47M)(49.18M)
Net Margin-436.0%-100.7%-14.6%-392.0%-1764.5%
EPS (Basic)(0.57)(0.73)(0.09)(0.61)(0.53)
EPS (Diluted)(0.57)(0.73)(0.09)(0.61)(0.53)
Weighted Avg Shares79.54M79.59M84.11M81.05M89.42M
Weighted Avg Shares (Diluted)79.54M79.64M84.11M81.05M89.42M

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.